SCHEMBL1680137

SCHEMBL1680137

NCCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 9/20 1.00
PRKACA P17612 8/20 1.00
PRKACG P22612 8/20 1.00
PRKACB P22694 8/20 1.00
CDK4 P11802 3/20 0.80
CCND1 P24385 3/20 0.80
RPS6KB1 P23443 1/20 0.78
CCNB2 O95067 3/20 0.76
CDK1 P06493 3/20 0.76
CCNB1 P14635 3/20 0.76
CCNB3 Q8WWL7 3/20 0.76
PIM1 P11309 2/20 0.76
GSK3B P49841 2/20 0.76
MEN1 O00255 1/20 0.76
PRKD3 O94806 1/20 0.76
CCNE2 O96020 1/20 0.76
TP53 P04637 1/20 0.76
PRKCG P05129 1/20 0.76
CYP1A2 P05177 1/20 0.76
PRKCB P05771 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16371182 0.99 CAMK2D (0.98) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9086358 0.94 PRKACA (0.89) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9087193 0.90 CAMK2D (0.81) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9088300 0.90 CAMK2D (0.81) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9085479 0.89 CAMK2D (0.80) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9087034 0.89 CAMK2D (0.80) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9082921 0.89 CAMK2D (0.80) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9087420 0.89 CAMK2D (0.86) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9086912 0.89 PRKACA (0.80) CAMK2DPRKACAPRKACGPRKACBCDK4
SCHEMBL9085947 0.89 CAMK2D (0.82) CAMK2DPRKACAPRKACGPRKACBCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 US claimed
WO-2023039578-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION (US) 2023-03-16 WO claimed
EP-3878947-A2 MATURATION OF MAMMALIAN HEPATOCYTES Takara Bio Europe AB (SE) 2021-09-15 EP claimed
US-20210189332-A1 MATURATION OF MAMMALIAN HEPATOCYTES TAKARA BIO EUROPE AB (SE) 2021-06-24 US claimed
US-10941384-B2 Compositions and methods for promoting the generation of endocrine cells PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-03-09 US claimed
US-10913932-B2 Maturation of mammalian hepatocytes TAKARA BIO EUROPE AB (SE) 2021-02-09 US claimed
US-20190024044-A1 MATURATION OF MAMMALIAN HEPATOCYTES TAKARA BIO EUROPE AB (SE) 2019-01-24 US claimed
WO-2018204829-A1 METHODS FOR PREVENTING NEURAL TUBE DEFECTS IN DIABETIC PREGNANCY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2018-11-08 WO claimed
EP-3303566-A2 MATURATION OF MAMMALIAN HEPATOCYTES Takara Bio Europe AB (SE) 2018-04-11 EP claimed
US-20180066327-A1 Methods to Accelerate Wound Healing in Diabetic Subjects JOSLIN DIABETES CENTER, INC. 2018-03-08 US claimed
US-20120208750-A1 USE OF PROTEIN KINASE C DELTA (PKCD) INHIBITORS TO TREAT DIABETES, OBESITY, AND HEPATIC STEATOSIS JOSLIN DIABETES CENTER, INC. (US) 2012-08-16 US claimed
EP-2482837-A2 USE OF PROTEIN KINASE C DELTA (PKCD) INHIBITORS TO TREAT DIABETES, OBESITY, AND HEPATIC STEATOSIS Joslin Diabetes Center, Inc. (US) 2012-08-08 EP claimed
WO-2011041385-A2 USE OF PROTEIN KINASE C DELTA (PKCD) INHIBITORS TO TREAT DIABETES, OBESITY, AND HEPATIC STEATOSIS JOSLIN DIABETES CENTER, INC. (US) 2011-04-07 WO claimed
WO-2008079980-A1 INHIBITORS OF PROTEIN KINASE C-DELTA FOR THE TREATMENT OF GLAUCOMA ALCON RESEARCH, LTD. (US) 2008-07-03 WO claimed
US-20080153903-A1 INHIBITORS OF PROTEIN KINASE C-DELTA FOR THE TREATMENT OF GLAUCOMA ALCON MANUFACTURING, LTD. (US) 2008-06-26 US claimed
US-20060099568-A1 Signals and molecular species involved in senescence SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2006-05-11 US claimed
WO-2003104482-A1 SIGNALS AND MOLECULAR SPECIES INVOLVED IN SENESCENCE METABOLIC ENGINEERING LABORATORIES CO., LTD. (KR) 2003-12-18 WO claimed
US-6284783-B1 Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis THE UAB RESEARCH FOUNDATION 2001-09-04 US claimed
WO-1999041984-A9 INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) HUTCHINSON FRED CANCER RES (US) 1999-11-04 WO claimed
WO-1999041984-A1 INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) FRED HUTCHINSON CANCER RESEARCH CENTER (US) 1999-08-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER TP53, CD4, MCL1 CAMK2D 2343/4885PRKACA 2496/4885PRKACG 2480/4885
US-10941384-B2 Compositions and methods for promoting the generation of endocrine cells IAPP, GPR119, PNLIP CAMK2D 1411/4885PRKACA 319/4885PRKACG 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.